CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

Active filtersClassification:Core

Showing 157-168 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Terada T; Suzuki T; Ohnuki K; Yoshikawa T; Shimomura M; Shoda K; Amaishi Y; Takeichi K; Kudo M; Sugimoto M; Kobayashi S; Takenouchi K; Tsukamoto N; Gotohda N; Okamoto S; Nakatsura T

Jan 1, 2026Cancer letters

2026PubMedDirectly related

Nano meets CAR-T: A new era in cancer immunotherapy.

Ibrahim A; Nasr M

Jan 1, 2026Biochimica et biophysica acta. Reviews on cancer

2026PubMedDirectly related

In vivo CAR-T therapy: The shift from ex vivo culturing to direct in situ immune reprogramming.

Gopalakrishnan J; Rathod B; Puri S

Jan 1, 2026International immunopharmacology

2026PubMedDirectly related

Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.

Zi G; Zhang L; Zhou L; Liu X; Wang L; Zhou R; Zheng P; Wei J; Chen X; Wei S

Jan 1, 2026Signal transduction and targeted therapy

2026PubMedDirectly related

Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future Directions.

Raza A; Raza MA; Khan J; Ajazuddin

Jan 1, 2026Pathology, research and practice

2026PubMedDirectly related

Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy.

Lin X; Li Y; Shen X; Li B; Xu Y

Jan 1, 2026Molecular therapy : the journal of the American Society of Gene Therapy

2026PubMedDirectly related

Engineered immune cells and extracellular vesicles target tumour microenvironment barriers in solid tumour immunotherapy.

Zhou X; Chen S; Liang J

Jan 1, 2026Discover oncology

2026PubMedDirectly related

Cytokine circuitries as determinants of response, resistance, and toxicity across cancer immunotherapy platforms.

Mukherjee A

Jan 1, 2026Cytokine & growth factor reviews

2026PubMedDirectly related

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

Hu Z; Matsuo H; Du S; Berzain Battioni C; Jassowicz L; Carretero R; Sator-Schmitt M; Zhao X; Miao B; Eris C; Engel H; Mahmoud MAA; Laport E; Xiao Y; Hofmann I; Herold-Mende C; Sun C

Jan 1, 2026Immunity

2026PubMedDirectly related

Establishment of a scalable engineered cell-line platform for direct, GMP-grade production of eVLP vectors enabling streamlined generation of gene-edited CAR-T/NK cells.

Lin W; Shi J; Chen H; Chai R; Zhu S; Chen L; Mo S; Wang Z; Li H; Feng Y; Zhao L; Chen J; Yu G; Lu T; Wang J

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

CD8(+) stem cell-like memory T cells: Unveiling the potential for next-generation vaccination strategies.

Nguema L; Lévy Y; Godot V

Jan 1, 2026Cell reports. Medicine

2026PubMedDirectly related

Mass Spectrometry in Allogeneic CAR-T Cell Manufacturing: From Cellular Starting Materials to Multi-Attribute Quality Control.

Kim N; Huang Z; Born M; Camperi J

Jan 1, 2026Cells